News and Events
2010
July 26, 2010
Seaside Therapeutics Reports Data from Randomized, Placebo-Controlled Phase 2 Study in Fragile X Syndrome
July 20, 2010
Seaside Therapeutics Appoints Leading Industry Executives to its Board of Directors
February 10, 2010
Seaside Therapeutics Announces Issuance of Key Patent for Treatment of Autism Spectrum Disorders
January 6, 2010
Seaside Therapeutics and Vanderbilt University Enter Collaborative Research Agreement to Discover Novel Therapeutics to Treat Disorders of Brain Development
2009
December 16, 2009
Seaside Therapeutics Appoints Tanya Lewis to the Key Position of
Vice President, Regulatory Affairs and Quality Assurance
November 2, 2009
Seaside Therapeutics Initiates Clinical Development of Novel Treatment for Fragile X Syndrome
October 14, 2009
Seaside Therapeutics Recruits Industry Veterans to Accelerate Development of Candidates for Autism and Fragile X Syndrome
September 17, 2009
Seaside Therapeutics Secures $30 Million Financing: Funding to Support Clinical Studies in Autism and Fragile X Syndrome
2008
September 30, 2008
Seaside receives $2.59M NIH Grant “Development of mGluR5 Antagonists to treat Fragile X Syndrome and Autism” (3U01 MH078270- 02S1). Grant funded by National Institute of Child Health Development (NICHD) and the Best Pharmaceutical for Children’s Act
September 15, 2008
Seaside Therapeutics Appoints Dr. Paul Wang to the Key Position of Vice President, Clinical Development
February 8, 2008
Grant bolsters ‘Fragile X’ research
February 4, 2008
Seaside Therapeutics Awards $4.5 Million Collaborative Research Contract to Vanderbilt University Medical Center
2007
December 20, 2007
Seaside Awarded $3.37 Million Grant to Develop First Medications for Fragile-X Syndrome, Leading Inherited Cause of Mental Retardation
Funded by National Institute of Mental Health (NIMH), National Institute of Neurologic Disorders and Stroke (NINDS), National Institute of Child Health Development (NICHD), Cure Autism Now (CAN) and FRAXA Research Foundation
2006
September 15, 2006
Seaside Therapeutics Awarded Grant from Autism Speaks to Evaluate Therapeutic Potential of Proprietary MGLUR5 Antagonists in Animal Models of Autism
August 2, 2006
Seaside Therapeutics Announces Formation of Board of Directors
August 2, 2006
Seaside Therapeutics Announces Formation of Scientific Advisory Board with Appointments of Prominent Researchers
July 31, 2006
Seaside Therapeutics Announces Key Leadership Appointment of Dr. Timothy D. Ocain to the Position of Senior Vice President, Research and Development
|
